Kadcyla is made of trastuzumab conjugated via a non-cleavable linker to the microtubule disrupting agent emtansine and it is approved for the treatment of metastatic ErbB2-expressing breast and gastric cancer. Here, ERBB2 is linked to gastric cancer.